​

​

​

Three months ended

​

2025

2024

​

​

​

​

​

​

​

​

Product revenue, net

​

​

$

168

​

$

582

Less:

​

​

​

​

​

​

​

Cost of goods sold

​

​

$

14

​

$

80

Research and development costs:

​

​

​

​

​

​

​

Personnel and related costs

​

​

$

1,682

​

$

3,630

Non-cash stock-based compensation

​

​

​

(514)

​

​

1,281

Professional fees

​

​

​

779

​

​

1,307

Clinical trials expense

​

​

​

2,018

​

​

4,068

Chemical, manufacturing and controls cost

​

​

​

175

​

​

549

Other expenses

​

​

​

414

​

​

566

Total research and development costs

​

​

$

4,554

​

$

11,401

Commercial costs:

​

​

​

​

​

​

​

Personnel and related costs

​

​

​

79

​

​

1,149

Non-cash stock-based compensation

​

​

​

—

​

​

268

Professional fees

​

​

​

38

​

​

71

Commercial and marketing

​

​

​

169

​

​

1,347

Travel related expenses

​

​

​

9

​

​

117

Other expenses

​

​

​

(88)

​

​

196

Total commercial costs

​

​

$

207

​

$

3,148

Selling, general and administrative costs:

​

​

​

​

​

Personnel and related costs

​

​

$

993

​

$

2,037

Non-cash stock-based compensation

​

​

694

​

​

1,884

Professional fees

​

​

2,834

​

​

5,240

Travel related expenses

​

​

​

116

​

​

247

Other expenses

​

​

855

​

​

708

Total selling, general and administrative costs

​

​

$

5,492

​

$

10,116

Total operating expenses

​

​

$

10,267

​

$

24,745

Other (income) expense

​

​

​

Interest expense

​

​

3,993

​

3,607

Interest income

​

​

​

(279)

​

​

(947)

Other (income) expense, net

​

​

​

(6,559)

​

​

(32)

Segment net loss

​

​

$

(7,254)

​

$

(26,791)

Adjustments and reconciling items

​

​

​

—

​

​

—

Consolidated Net Loss

​

​

$

(7,254)

​

$

(26,791)